A practical PT-141 peptide dosage chart covering subcutaneous, nasal spray, and 10 mg options, plus timing, safety notes, and what research shows.
The PT-141 peptide dosage chart below summarizes the most commonly cited bremelanotide doses: 1.75 mg injected under the skin (the FDA-approved Vyleesi dose) and about 10 mg by nasal spray in older research. PT-141 is approved only for premenopausal women with hypoactive sexual desire disorder, so every other use is off-label or research-only. Dosing should be guided by a healthcare professional because side effects such as nausea and blood pressure changes are dose-related.
PT-141 at a Glance: What the Peptide Does
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors in the brain. It is not an aphrodisiac in the classic sense and does not work like Viagra or other PDE5 inhibitors. Instead, it acts on pathways tied to sexual desire.
The FDA approved bremelanotide under the brand name Vyleesi in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is not approved for men, and it is not approved as a nasal spray or an oral product.
PT-141 Peptide Dosage Chart by Route
Doses differ widely by route because the nasal spray delivers less drug into the bloodstream than an injection. The chart below groups the most frequently discussed options.
| Route | Typical dose | Timing | FDA status |
|---|---|---|---|
| Subcutaneous injection | 1.75 mg | At least 45 minutes before activity | Approved (Vyleesi) |
| Subcutaneous off-label | 1–2 mg | 45–60 minutes before | Not approved |
| Nasal spray | 10 mg (studied) | About 30–60 minutes before | Not approved |
| Nasal spray (women, forum-reported) | 10 mg | Varies | Not approved |
| Oral or sublingual | Not established | — | Not approved |
No standard dose exists for men or for people using PT-141 outside the approved indication. A peptide PT-141 dosage chart is a reference, not a prescription.
Subcutaneous Dosing: The Approved 1.75 mg and Off-Label Ranges
For pt-141 dosage subcutaneous use, the approved regimen is simple: 1.75 mg injected into the abdomen or thigh. The manufacturer advises injecting at least 45 minutes before anticipated sexual activity.
Frequency limits matter as much as the dose:
- Maximum one dose in 24 hours.
- No more than 8 doses in a month.
- Do not combine with other bremelanotide products.
Some researchers and clinicians have studied 1.25 mg and 2.25 mg doses, but 1.75 mg became the approved dose based on the balance of benefit and side effects. Higher doses increase nausea and flushing without a clear gain in effectiveness.
Nasal Spray and 10 mg Dosing for Women
Before the autoinjector, bremelanotide was studied as a pt-141 peptide nasal spray. In those trials, nasal doses were much higher—often 10 mg or 20 mg—because the nasal route absorbs a smaller fraction of the drug.
That history is why pt-141 10mg dosage women searches are common. A 10 mg nasal dose is not equivalent to a 10 mg injection. Anyone comparing a nasal spray dose to an injectable dose is comparing two different delivery systems, not two strengths of the same product.
Nasal bremelanotide is not FDA-approved. The approved product is the 1.75 mg subcutaneous injection only.
Timing, Onset, and Duration
Timing affects how well PT-141 works. The approved injection is given at least 45 minutes before activity, and effects can last for several hours. Some users report a window of 1 to 6 hours.
Nasal sprays are often reported to act within 30 to 60 minutes, but absorption is less predictable. Food does not appear to have a major effect on the injection, though individual responses vary.
PT-141 is not a daily medication. It is taken only when needed, with strict limits on how often it can be used.
Safety, Side Effects, and Legal Status
Common side effects include nausea, flushing, headache, and injection-site reactions. Nausea is the most frequent reason people stop using it.
PT-141 can raise blood pressure and lower heart rate temporarily. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. It should not be used with certain medications, and it is not recommended during pregnancy.
PT-141 is not FDA-approved for men, for nasal use, or for general sexual enhancement. Buying it online as a "research chemical" means the product is not regulated for human use, and purity is not guaranteed.
Reviews, Sourcing, and What Users Report
Online pt-141 peptide reviews are mixed. Some women report improved desire, while others describe nausea or no noticeable effect. Reviews are anecdotal and cannot replace clinical evidence.
Searchers often look for a pt 141 peptide buy online usa source. Many of those listings sell peptides labeled "for research use only," which means they are not intended for human consumption. The only FDA-approved PT-141 product requires a prescription.
Bottom Line on PT-141 Dosing
PT-141 dosing is not one-size-fits-all. The only approved dose is 1.75 mg subcutaneously for premenopausal women with HSDD. Nasal and 10 mg doses come from older research and are not FDA-approved.
Anyone considering PT-141 should talk with a healthcare professional about risks, interactions, and whether an approved option fits their situation.
Frequently Asked Questions
How much PT-141 should I take?
The only FDA-approved dose is 1.75 mg injected subcutaneously for premenopausal women with hypoactive sexual desire disorder. There is no established standard dose for men, nasal use, or oral use. A healthcare professional should determine whether PT-141 is appropriate and what dose, if any, is safe for you.
Is PT-141 the same as the nasal spray?
No. The FDA-approved product, Vyleesi, is a 1.75 mg subcutaneous autoinjector. Bremelanotide was studied as a nasal spray at doses around 10 mg to 20 mg, but nasal PT-141 is not FDA-approved. The higher nasal doses reflect poor absorption through the nose, not a stronger effect.
How long does PT-141 last?
Effects are typically reported within 45 minutes to an hour after injection and can last for several hours, sometimes up to six. PT-141 should not be used more than once in 24 hours or more than eight times per month. Individual timing and intensity vary.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.